Company Overview
| Stock Name | 福森藥業有限公司 |
|---|---|
| Stock Code | 01652 |
| Company Full Name | 福森藥業有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 公司主要於中國從事制造及銷售藥品。 |
| Listing Date | 2018-07-11 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國河南省淅川縣城區工業園區 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.fusenyy.com |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 2.08 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 41,600,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 2.54 |
|---|---|
| First Day Open | HK$ 2.33 |
| First Day Change | 22.12% |
| First Day Volume | 72934000.0 |
| First Day Turnover | 180523000.0 |
Use of Proceeds
| Use of Proceeds | 1、約30%或112.4百萬港元將用于擴充計劃； 2、約10%或37.4百萬港元將用于產品廣告及營銷； 3、約10%或37.4百萬港元將用于擴展現有營銷及分銷網絡，以提高市場滲透水平，覆蓋更多最終客戶，從而增加市場占有率； 4、約10%或37.4百萬港元將用于繼續進行研究及開發活動，尤其是為與外部合作伙伴合作進行的研究項目提供資金； 5、約15%或56.1百萬港元將用于并購治療領域與我們目前重點治療領域類似的中成藥飲片及顆粒劑或其他西藥生產商，以拓展產品組合及增強競爭優勢； 6、約15%或56.1百萬港元將用作收購中成藥或其他西藥的生產許可證，以拓展產品組合； 7、約10%或約37.4百萬港元將用于為營運資金及其他一般企業用途提供資金。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
中信建投（国际）融资有限公司 CE BAU112
Overall Coordinators (3)
中信建投（国际）融资有限公司 CE BAU112
农银国际融资有限公司 CE AWL249
Bluemount Securities Limited CE BHR496
Joint Bookrunners (6)
中信建投（国际）融资有限公司 CE BAU112
农银国际融资有限公司 CE AWL249
Bluemount Securities Limited CE BHR496
Dongxing Securities (Hong Kong) Company Limited CE BBY779
HEAD & SHOULDERS SECURITIES LIMITED CE AFS455
GF Securities (Hong Kong) Brokerage Limited CE AOB364
Joint Lead Managers (6)
中信建投（国际）融资有限公司 CE BAU112
农银国际证券有限公司 CE ACX411
Bluemount Securities Limited CE BHR496
Dongxing Securities (Hong Kong) Company Limited CE BBY779
HEAD & SHOULDERS SECURITIES LIMITED CE AFS455
GF Securities (Hong Kong) Brokerage Limited CE AOB364
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 曹智銘 |
|---|---|
| Company Secretary | 楊育康 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 曹長城及家族成員(70.13%);Vistra Trust (Hong Kong) Limited(23.91%);林曉波(5.27%) |
|---|
